| HOME | HELP | FEEDBACK | ARCHIVE | SUBSCRIPTIONS |
|
|
|
|||||
|
|||||||
Original Article |
1 Department of Epidemiology and Public Health, Imperial College London, UK
2 Department of Community and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA
3 Division of Clinical Epidemiology, German Cancer Research Centre, Heidelberg, Germany
4 Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
5 Department of Medicine, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
6 Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
7 Department of Epidemiology, German Institute of Human Nutrition, Potsdam, Germany
8 Department of Hygiene and Epidemiology, School of Medicine, University of Athens, Greece
9 Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
10 Hellenic Health Foundation, Greece
11 Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
12 Cancer Registry and Environmental Epidemiology Division, National Cancer Institute, Milan, Italy
13 CPO-PIemonte and ISI Foundation, Torino, Italy
14 Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Netherlands
15 National Institute for Public Health and the Environment, Centre for Nutrition and Health, Bilthoven, The Netherlands
16 Public Health Institute of Navarra, Pamplona, Spain
17 Epidemiology Department, Murcia Health Council, Spain
18 CIBER en Epidemiologia y Salud Publica (CIBERESP), Spain
19 Epidemiology Unit, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
20 Department of Public Health of Gipuzkoa, San Sebastian, Spain
21 Department of Public Health and Clinical Medicine, Nutrition. Umeå University, Sweden
22 Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
23 Department of Clinical sciences, Malmö University Hospital, Malmö, Sweden
24 Department of Surgery, Malmö University Hospital, Malmö, Sweden
25 Cancer Research UK, Epidemiology Unit, University of Oxford, UK
26 MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, Department of Public Health and Primary Care, University of Cambridge, UK
27 MRC Epidemiology Unit, Elsie Widdowson Laboratory, Cambridge, UK
28 Nutrition and Hormones Group, International Agency for Research on Cancer, Lyon, France
29 Gene-Environment Epidemiology Group, International Agency for Research on Cancer, Lyon, France
30 Department of Epidemiology and Public Health, Imperial College London, London, UK
Correspondence: Paolo Vineis, Department of Epidemiology and Public Health, Imperial College London, Room 151, St Mary’s Campus, Norfolk Place W2 1PG, London, UK. E-mail:p.vineis{at}imperial.ac.uk
ABSTRACT
Background: The incidence of non-Hodgkin lymphoma and multiple myeloma is increasing steadily. It has been hypothesized that this may be due, in part, to the parallel rising prevalence of obesity. It is biologically plausible that anthropometric characteristics can infuence the risk of non-Hodgkin lymphoma and multiple myeloma.
Design and Methods: In the contest of the European Prospective Investigation into Cancer and Nutrition (EPIC), anthropometric characteristics were assessed in 371,983 cancer-free individuals at baseline. During the 8.5 years of follow-up, 1,219 histologically confirmed incident cases of non-Hodgkin lymphoma and multiple myeloma occurred in 609 men and 610 women. Gender-specific proportional hazards models were used to estimate relative risks and 95% confidence intervals (95% CI) of development of non-Hodgkin lymphoma and multiple myeloma in relation to the anthropometric characteristics.
Results: Height was associated with overall non-Hodgkin lymphoma and multiple myeloma in women (RR 1.50, 95% CI 1.14–1.98) for highest versus lowest quartile; p-trend < 0.01) but not in men. Neither obesity (weight and body mass index) nor abdominal fat (waist-to-hip ratio, waist or hip circumference) measures were positively associated with overall non-Hodgkin lymphoma and multiple myeloma. Relative risks for highest versus lowest body mass index quartile were 1.09 (95% CI 0.85–1.38) and 0.92 (95% CI 0.71–1.19) for men and women, respectively. Women in the upper body mass index quartile were at greater risk of diffuse large B-cell lymphoma (RR 2.18, 95% CI 1.05–4.53) and taller women had an elevated risk of follicular lymphoma (RR 1.25, 95% CI 0.59–2.62). Among men, height and body mass index were non-significantly, positively related to follicular lymphoma. Multiple myeloma risk alone was elevated for taller women (RR 2.34, 95% CI 1.29–4.21) and heavier men (RR 1.77, 95% CI 1.02–3.05).
Conclusions: The EPIC analyses support an association between height and overall non-Hodgkin lymphoma and MM among women and suggest heterogeneous subtype associations. This is one of the first prospective studies focusing on central adiposity and non-Hodgkin lymphoma subtypes.
Key words: non-Hodgkin’s lymphoma, anthropometry, cohort study.
| HOME | HELP | FEEDBACK | ARCHIVE | SUBSCRIPTIONS |
